• Provide written informed consent or assent (per local regulation), prior to the conduct of any study-related procedure. Participants who provide assent must have a parent, guardian, or legal representative provide written informed consent.

• Be between 12 and 50 years of age (inclusive) at the time of informed consent and assent (as applicable).

• Be male (XY chromosome) and have at least one documented pathogenic or likely pathogenic variant in the RPGR gene.

• Have a clinical diagnosis of XLRP.

• Be able and willing, as assessed by the Investigator, to follow study instructions, complete study assessments, comply with the protocol, and attend study visits for the duration of the study.

• Ocular Inclusion Criteria (Study Eye):

• Have a BCVA ≤ 78 letters (approximately Snellen, 20/32) and ≥ 34 letters (approximately Snellen, 20/200)

• Have a LLVA ≤64 letters (approximately Snellen 20/50) in the study eye

• Be able to perform all tests of visual and retinal function and structure in both eyes based on the participant's reliability, and fixation, in the study eye per the Investigator's discretion.

• Have an LLD of \> 10 letters in the study eye

⁃ Have detectable baseline mean macular sensitivity measured by MAIA microperimetry, between 1-12 decibels (dB) in the study eye, as determined by the Investigator and confirmed by the CRC with fixation loss ≤20% at each screening visit.

⁃ Have a detectable sub-foveal EZ line in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT) and confirmed by the CRC.